Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.
Profitability
This table compares Akebia Therapeutics and CollPlant Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akebia Therapeutics | -13.54% | -88.88% | -7.74% |
| CollPlant Biotechnologies | -683.68% | -218.81% | -139.28% |
Analyst Recommendations
This is a summary of current ratings and target prices for Akebia Therapeutics and CollPlant Biotechnologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
Valuation and Earnings
This table compares Akebia Therapeutics and CollPlant Biotechnologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akebia Therapeutics | $236.20 million | 1.07 | -$5.34 million | ($0.11) | -8.32 |
| CollPlant Biotechnologies | $2.37 million | 2.77 | -$11.49 million | ($14.50) | -0.31 |
Akebia Therapeutics has higher revenue and earnings than CollPlant Biotechnologies. Akebia Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Akebia Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500.
Insider and Institutional Ownership
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Akebia Therapeutics beats CollPlant Biotechnologies on 9 of the 14 factors compared between the two stocks.
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
